Filing Flows › Biodesix (BDSX) › R&D spending
Biodesix (BDSX) R&D spending by quarter
Biodesix's R&D spending was $3.0M in Q3 2026 (third quarter 2026), -4% from Q2 2026. Over the last 7 quarters it ranged from $2.9M (Q4 2025) to $3.3M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.0M | -4% | +0.1% |
| Q2 2026 | $3.1M | -5% | -4% |
| Q1 2026 | $3.3M | +14% | +14% |
| Q4 2025 | $2.9M | -4% | — |
| Q3 2025 | $3.0M | -8% | — |
| Q2 2025 | $3.3M | +14% | — |
| Q1 2025 | $2.9M | — | — |
Q3 2026 at a glance
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biodesix's R&D spending?
Biodesix's R&D spending was $3.0M in Q3 2026 (third quarter 2026), -4% from Q2 2026.
How has Biodesix's R&D spending changed?
Over the last 7 quarters it ranged from $2.9M (Q4 2025) to $3.3M (Q1 2026).